Promising combo study for HER2+ breast cancer halted early
NCT ID NCT04108858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at adding a drug called copanlisib to standard targeted therapy (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that had spread and had specific gene changes (PIK3CA or PTEN). The goal was to see if the combination was safe and could help control the cancer longer. Only 2 people enrolled before the study was stopped, so results are very limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Could a gentler chemo work for older breast cancer patients?
- Genetic clues in blood and tumors could personalize breast cancer care
- Can couples coping together ease the burden of advanced cancer?
- Blood test could track breast cancer in real time